Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual CD33-CLL1 CAR-T in R/R AML
NCT05016063Phase 1Unknown
- Sponsor
- Xinqiao Hospital
- Start
- Sep 2021
- Primary completion
- Sep 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dual CD33-CLL1 CAR-T cells in acute myeloid leukemia (AML), sponsored by Xinqiao Hospital. Primary endpoints: Overall Response Rate at 4 weeks and Safety Evaluation at 4 weeks. Status: unknown.
02
Drugs
dual CD33-CLL1 CAR-T cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05016063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05016063.